Here, a reduction in PB TCR diversity was found in patients with higher CEA levels prior to initiating treatment, indicating that PB TCR diversity may indicate tumor recurrence and metastasis and is a prognostic factor for CRC and NSCLC patients. Here, CEACAM5 is linked to non-small cell lung carcinoma.